Guardant and Zephyr AI Partner to Advance Cancer Biomarker Development
Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, aiming to improve precision oncology in healthcare.
By combining their expertise, the companies expect to establish a model that will drive insights into cancer biomarkers, particularly in targeted therapy selection and drug response monitoring.
- Guardant’s multimodal molecular DNA repository will be combined with Zephyr’s AI/ML capabilities.
- The partnership aims to accelerate research and development for biopharma partners.
Pairing Guardant multimodal real-world data and precision oncology insights with Zephyr’s proprietary AI technologies will accelerate research and development.
Author's summary: Guardant and Zephyr AI team up to improve cancer treatment.
More News
- Man Utd Failed With £50 Million Mbeumo Alternative
- 5 members of the 2025 Yankees make list of top 50 free agents
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Three resilient UK multinationals global managers are excited about | Trustnet
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Morocco Showcases Energy Transition Strategies at Green Policy Forum in Sweden
- NCGA president understands challenge - High Plains Journal
- Battlefield 6 REDSEC battle royale to officially launch soon